CRBU

Price & events

Pipeline stages · 3 programs

Pipeline · 3 trials · 1 upcoming

Catalyst news & presentations · 11

• second half of 2026Guided 55%readoutPhase 1CB-011 · Initial dose expansion data from CaMMouflage trial.SEC 8-K
• 2026-08-12earningsEarningsEarnings releaseyahoo
• June 14, 2026conferencedata presentationsecondaryPhase 1CB-011 · Oral presentation of CaMMouflage phase1 data at EHA2026.SEC 8-K
• June 12, 2026conferencedata presentationsecondaryPhase 1vispa-cel (CB-010) · Oral presentation of ANTLER phase1 data at EHA2026.SEC 8-K
• second half of 2025conferencedata presentationsecondaryPhase 1CB-011 · Dose escalation data and recommended doses for expansion from CaMMouflage phase 1 trial, including initial safety and efficacy data on minimum 25 patients at multiple dose levels using deeper lymphodepletion regimen.SEC 8-K
• second half of 2025conferencedata presentationsecondaryPhase 1CB-010 · Initial data from ANTLER phase 1 confirmatory cohort using partial HLA matching strategy in 2L LBCL patients and data from proof-of-concept cohort in LBCL patients relapsed after prior CD19-targeted therapy.SEC 8-K
• 2025-11-03safety signalvispacabtagene regedleucel (vispa-cel) · One vispa-cel-related grade 5 IEC-HS observedSEC 8-K
• first half of 2025readoutPhase 1CB-011 · CaMMouflage phase 1 dose escalation dataSEC 8-K
• first half of 2025readoutPhase 1CB-010 · ANTLER phase 1 clinical trial data from additional second line and prior CD19 relapsed patientsSEC 8-K
• 2025-04-24trial discontinuedCB-012 · AMpLify phase 1 trial in relapsed/refractory AML discontinued as additional data needed to advance program.SEC 8-K
• 2025-04-24trial discontinuedCB-010 · GALLOP phase 1 trial in lupus discontinued prior to dosing first patient.SEC 8-K